MUC1 Peptide-Poly-ICLC Vaccine

BIOLOGICAL2 trials

Sponsors

National Cancer Institute (NCI)

Conditions

Colorectal AdenomaColorectal CarcinomaColorectal Conventional Adenoma With Severe DysplasiaColorectal Tubulovillous AdenomaLung Carcinoma

Phase 1

MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer

Active, not recruitingNCT03300817

National Cancer Institute (NCI)Lung Carcinoma

Start: 2017-12-27End: 2026-12-01Updated: 2026-07-31

Phase 2

Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps

Active, not recruitingNCT02134925

National Cancer Institute (NCI)Colorectal Adenoma, Colorectal Carcinoma, Colorectal Conventional Adenoma With Severe Dysplasia +1

Start: 2014-06-23End: 2027-03-09Updated: 2026-09-11

Related Papers

Immune cell transcriptional profiles from pre-vaccination peripheral blood predict immune response to preventative MUC1 cancer vaccine.

2025-08-051 citations

Abstract 6537: Single cell transcriptomics uncovers cellular and molecular differences in PBMCs of responders and non-responders to the MUC1 cancer vaccine given in the preventative setting

Cancer Research2023-04-04